SOMS-2 symptoms	Male (%)	Female (%)	All patients (%)
1	86%	71%	79%
2	71%	71%	71%
3	86%	57%	71%
4	71%	43%	57%
5	29%	71%	50%
6	86%	71%	79%
7	0%	14%	7%
8	14%	14%	14%
9	29%	29%	29%
10	57%	86%	71%
11	71%	71%	71%
12	86%	86%	86%
13	14%	14%	14%
14	57%	14%	36%
15	43%	14%	29%
16	14%	29%	21%
17	43%	29%	36%
18	43%	29%	36%
19	57%	29%	43%
20	43%	14%	29%
21	0%	0%	0%
22	14%	43%	29%
23	14%	0%	7%
24	57%	86%	71%
25	86%	57%	71%
26	86%	29%	57%
27	71%	29%	50%
28	43%	43%	43%
29	43%	57%	50%
30	71%	86%	79%
31	29%	29%	29%
32	43%	29%	36%
33	0%	57%	29%
34	57%	43%	50%
35	57%	29%	43%
36	29%	43%	36%
37	0%	0%	0%
38	0%	0%	0%
39	0%	0%	0%
40	0%	0%	0%
41	100%	71%	86%
42	14%	14%	14%
43	0%	0%	0%
44	0%	0%	0%
45	0%	0%	0%
46	14%	0%	7%
47	0%	0%	0%
48		71%	71%

49		14%	14%
50		29%	29%
51		14%	14%
52		14%	14%
53	29%		29%

## B. Mean (M) and standard deviation (SD) of SOMS-2 indexes in clinical group.

	Male (M±SD)	Female (M±SD)	All patients (M±SD)
Total SOMS-2	18.57 ± 6.21	26.86 ± 5.93	22.71 ± 7.25
Somatization	7441204	7.00   4.04	7.07   4.00
Index ICD-10	7.14 ± 2.04	7.00 ± 1.91	7.07 ± 1.90
Somatization			
Index DSM-IV	9.14 ± 3.67	9.43 ± 2.51	9.29 ± 3.02

## C. Duration of symptoms in clinical group.

Duration	Male (%)	Female (%)	All patients (%)
less than			
6 months	0%	0%	0%
6-12			
months	0%	11%	6%
1-2			
years	14%	22%	19%
more than			
2 years	86%	67%	75%